Daily Newsletter

29 September 2023

Daily Newsletter

29 September 2023

Fabre-Kramer gains FDA approval for major depressive disorder therapy

Exxua, which was studied in more than 5,000 patients, demonstrated an overall acceptable safety profile.

RanjithKumar Dharma September 29 2023

Fabre-Kramer Pharmaceuticals has obtained approval from the US Food and Drug Administration (FDA) for Exxua (gepirone hydrochloride extended-release tablets) to treat major depressive disorder (MDD) in adult patients.

Exxua is the first and only approved antidepressant with a new action mechanism that selectively acts on the serotonin 1A receptor, a crucial mood and emotion regulator.

The company plans to make the oral selective serotonin (5HT) 1a receptor agonist Exxua available in pharmacies from the start of 2024.

Exxua, which was studied in more than 5,000 patients, reduces depressive symptoms with an acceptable side-effect profile.

Sexual side effects observed during clinical trials of Exxua were comparable to those reported in the placebo and did not meet the criteria for inclusion in the adverse reaction section of its label.

There was no significant adverse effect on blood pressure, heart rate, weight or liver function and the therapy demonstrated an overall acceptable safety profile.

Fabre-Kramer CEO Stephen Kramer stated: “Exxua represents an important milestone in the treatment of MDD, a serious and debilitating condition that affects millions of people worldwide.

“There is value in providing prescribers and patients with a wide range of effective options for use in clinical practice. We are proud to bring this innovative therapy to patients who need a new option to manage their depression and improve their quality of life.”

Exxua is also in development for other psychiatric disorders.

Fabre-Kramer is focused on the development and commercialisation of new medications for neurology and psychiatry disorders.

M&A in the Contract Manufacturing Industry

Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.